Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling (2019)
Lin, Chi-Chuan; Suen,Kin Man; Stainthorp,Amy; Wieteska,Lukasz; Biggs,George S.; Leitão, Andrei 
; Montanari, Carlos Alberto ; Ladbury, John E.,
Fonte: Cancer Letters. Unidade: IQSC
Assunto: NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIN, Chi-Chuan et al. Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling. Cancer Letters, v. 457, p. 86-97, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.canlet.2019.05.008. Acesso em: 03 out. 2024.APA
Lin, C. -C., Suen, K. M., Stainthorp, A., Wieteska, L., Biggs, G. S., Leitão, A., et al. (2019). Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling. Cancer Letters, 457, 86-97. doi:10.1016/j.canlet.2019.05.008NLM
Lin C-C, Suen KM, Stainthorp A, Wieteska L, Biggs GS, Leitão A, Montanari CA, Ladbury JE. Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling [Internet]. Cancer Letters. 2019 ;457 86-97.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.canlet.2019.05.008Vancouver
Lin C-C, Suen KM, Stainthorp A, Wieteska L, Biggs GS, Leitão A, Montanari CA, Ladbury JE. Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling [Internet]. Cancer Letters. 2019 ;457 86-97.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.canlet.2019.05.008
